Eventide Asset Management, LLC 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-14 3:51 pm Unchanged | 2025-03-31 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Eventide Asset Management, LLC | 0 0.000% | 0 (Unchanged) | Filing |
| 2025-05-13 5:30 pm Sale | 2025-03-31 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Eventide Asset Management, LLC | 0 0.000% | -4,475,054 (Position Closed) | Filing |
| 2025-02-14 12:13 pm Sale | 2024-12-31 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Eventide Asset Management, LLC | 4,475,054 6.280% | -2,615,054 (-36.88%) | Filing |
| 2024-11-06 2:47 pm Sale | 2024-10-31 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Eventide Asset Management, LLC | 7,090,108 9.970% | -4,469,867 (-38.67%) | Filing |
| 2023-12-11 5:15 pm Purchase | 2023-11-30 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Eventide Asset Management, LLC | 11,559,975 16.340% | 3,745,936 (+47.94%) | Filing |
| 2023-10-10 3:40 pm Purchase | 2023-09-30 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Eventide Asset Management, LLC | 7,814,039 11.070% | 7,814,039 (New Position) | Filing |